of Human Biology
Human Cells
CurioChips
Patient-derived Data
Omics & Literature
Databases
Qureator Human Disease Models
Testing Modalities:
- Small molecule
- Biologics/Antibodies
- Cell & Genen Therapies
- CRISPRi
- etc…
New Target Identification
Discovery of Synergistic Combinations
Efficacy & Dosage Prediction
High Throughput MPS and AI
and Omics
Extraction
Analysis
Best Drug Candidates
Patient Stratification
Qureator’s Historic FDA IND Approval Based on Human-Relevant Data Highlighted in The BIO
Qureator extends its sincere appreciation to The BIO for its in-depth reporting on our landmark FDA IND approval achieved without animal PoC data. The coverage underscores a transformative moment for the global drug-development landscape and highlights the pivotal collaboration between Qureator and SillaJen.
Qureator and Physicians Committee for Responsible Medicine Announce Joint Workshop at SOT 2026
Qureator is proud to announce a new partnership with the Physicians Committee for Responsible Medicine (PCRM) to host an exclusive in-person workshop during the Society of Toxicology (SOT) 2026 Annual Meeting in San Diego. This collaboration reflects our shared commitment to advancing human-relevant, non-animal approaches in next-generation toxicology and risk assessment.
Paul Park Joins Qureator as Chief Business Officer
Qureator Appoints Paul Park as Consulting Chief Business Officer
We are thrilled to welcome Paul Park to Qureator as our new Consulting CBO. Paul brings over 20 years of executive experience from Amgen, Ionis, and Circle Pharma, with a proven track record in strategy, M&A, and high-impact partnerships.